explore -WSS

explore

author：explore 2025-10-02 21:06:31 - browse：4

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Elizabeth Warren probes abortion access

WSS

New rules on organ donation and transplantation 'will bring chaos'

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Court strikes down limits on filming of police in Arizona

Death toll from an explosion and collapse of a Paris building in June climbs to 3

EpiPen alternative approval delay highlights citizen petition issue

White House launches permanent pandemic office

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medical records are filled with copy

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Affirmative action in medical school literally saved lives

Biotech stock slump in 2023: awaiting the turnaround

What does generative AI mean for health care? We asked experts

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Wildfire smoke exposes gaps in outdoor worker protections

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Alkermes shareholders re

What to know about Saharan dust affecting the US and how it can affect health

entertainment

It's been 20 years since Dolly the sheep. Where's my clone?

Elizabeth Warren probes abortion access

Biotech stock slump in 2023: awaiting the turnaround

Changes to biosimilar regulatory framework must prioritize patients

Intarcia’s device

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

explore

entertainment

knowledge